Update information
September 2020: Section 2 of the guidance updated because the marketing authorisation holder changed from Chiesi Farmaceutici to Holostem Terapie Avanzate. The company contact details were removed from section 5 and updated details put on the overview page for the guidance.
Information in tables was presented in a different way, to meet accessibility requirements.
ISBN: 978-1-4731-2628-2